BW, serum glucose and lipid profile of NP-treated ApoE-null mice
| Treatment | Sex (n) | Initial BW (g) | Final BW (g) | Glucose (mg/dL) | Cholesterol (mg/dL) | Triglycerides (mg/dL) | HDL (mg/dL) |
|---|---|---|---|---|---|---|---|
| Vehicle | F (10) | 29.1 ± 3.4 | 31.0 ± 3.3 | 143.2 ± 18.0 | 434.4 ± 65.4 | 152.8 ± 72.8 | 2.7 ± 2.6 |
| M (10) | 31.5 ± 2.3 | 31.5 ± 4.6 | 149.2 ± 41.9 | 448.9 ± 95.2 | 182.0 ± 78.5 | 8.4 ± 3.3 | |
| Total (20) | 30.3 ± 2.9 | 31.3 ± 3.9 | 146.2 ± 29.9 | 441.6 ± 80.3 | 167.4 ± 75.7 | 5.6 ± 4.1 | |
| HSANP | F (10) | 28.4 ± 1.9 | 31.2 ± 3.6 | 143.9 ± 22.3 | 506.3 ± 139.3 | 169.1 ± 45.6 | 15.5 ± 9.2 |
| M (10) | 33.3 ± 1.6 | 34.5 ± 2.0 | 137.9 ± 9.5 | 446.8 ± 96.1 | 163.1 ± 41.2 | 15.4 ± 1.2 | |
| Total (20) | 30.8 ± 1.8 | 32.9 ± 2.8 | 140.9 ± 15.9 | 476.5 ± 11.7 | 166.1 ± 43.4 | 15.4 ± 12.3 | |
| HSANP-FLAGPP1 | F (5) | 31.1 ± 1.7 | 36.3 ± 30.7 | 175.0 ± 37.4 | 539.3 ± 224.2 | 250.1 ± 216.5 | 19.7 ± 6.3 |
| M (5) | 29.5 ± 1.6 | 30.7 ± 2.4 | 127.0 ± 19.4 | 394.8 ± 107.2 | 125.6 ± 56.2 | 14.2 ± 8.1 | |
| Total (10) | 30.3 ± 1.6 | 33.5 ± 2.9 | 151.0 ± 28.3 | 467.1 ± 165.7 | 187.8 ± 136.3 | 16.9 ± 11.6 (P = 0.028) | |
| S-HSANP-FLAGPP1 | F (10) | 27.0 ± 3.9 | 29.0 ± 3.7 | 148.7 ± 20.8 | 464.1 ± 108.3 | 147. ± 61.2 | 15.4 ± 11.8 |
| M (10) | 32.3 ± 3.5 | 31.7 ± 4.2 | 144.3 ± 28.1 | 489.1 ± 215.9 | 161.6 ± 46.1 | 16.3 ± 2.1 | |
| Total (20) | 29.6 ± 3.7 | 30.3 ± 4.0 | 146.5 ± 24.5 | 154.7 ± 53.6 | 476.6 ± 162.1 | 15.9 ± 13.8 | |
| SGI-HSA | F (5) | 29.6 ± 2.9 | 33.8 ± 2.2 | 177.0 ± 38.4 | 555.4 ± 300.9 | 261.2 ± 197.2 | 22.7 ± 13.5 |
| M (5) | 28.2 ± 2.1 | 31.6 ± 2.5 | 131.8 ± 23.0 | 311.7 ± 239.3 | 111.8 ± 91.6 | 12.0 ± 8.6 | |
| Total (10) | 28.9 ± 2.5 | 32.7 ± 2.3 | 154.4 ± 30.7 | 433.6 ± 270.1 | 186.5 ± 144.4 | 17.3 ± 15.4 (P = 0.020) |
F: female; M: male. Data are mean ± SD. Significance refers to comparison with vehicle control. Only significant P values are shown. ANOVA, Bonferroni post hoc test